Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013

(2016) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines

(2016) Matthias Riedel et al.   Oncotarget

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry

(2015) Pei Yang et al.   Oncotarget

A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy

(2015) Stephanie Ströbele et al.   PLoS One

Invasive Glioblastoma Cells Acquire Stemness and Increased Akt Activation

(2015) Jennifer R. Molina et al.   NEOPLASIA

PI3K/AKT signaling pathway and cancer: an updated review

(2014) Miriam Martini et al.   ANNALS OF MEDICINE

MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras

(2014) Zhumei Shi et al.   NEURO-ONCOLOGY

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone

(2014) Remco J. Molenaar et al.   NEURO-ONCOLOGY

Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling

(2014) M. Will et al.   Cancer Discovery

Role of Receptor Tyrosine Kinases and Their Ligands in Glioblastoma

(2014) Estefanía Carrasco-García et al.   Cells

Targeting PI3K/Akt/mTOR Signaling in Cancer

(2014) Camillo Porta et al.   Frontiers in Oncology

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells

(2013) P. O. Carminati et al.   MOLECULAR BIOLOGY REPORTS

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

Sensitivity of Glioblastomas to Clinically Available MEK Inhibitors Is Defined by Neurofibromin 1 Deficiency

(2012) W. L. See et al.   CANCER RESEARCH

The Definition of Primary and Secondary Glioblastoma

(2012) H. Ohgaki et al.   CLINICAL CANCER RESEARCH

Current clinical development of PI3K pathway inhibitors in glioblastoma

(2012) P. Y. Wen et al.   NEURO-ONCOLOGY

Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era

(2012) Christine Carico et al.   PLoS One

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Targeting the AKT Pathway in Glioblastoma

(2011) Kelli A. McDowell et al.   CURRENT PHARMACEUTICAL DESIGN

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide

(2011) G. Prasad et al.   NEURO-ONCOLOGY

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

(2011) V Serra et al.   ONCOGENE

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

(2011) V. S. Rodrik-Outmezguine et al.   Cancer Discovery

PTEN Signaling pathways in glioblastoma

(2010) Dimpy Koul   CANCER BIOLOGY & THERAPY

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells

(2009) N. Eckstein et al.   CANCER RESEARCH

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Mechanisms of drug combinations: interaction and network perspectives

(2009) Jia Jia et al.   NATURE REVIEWS DRUG DISCOVERY

The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair

(2009) M -A Westhoff et al.   ONCOGENE

Protein Kinase G Controls Brown Fat Cell Differentiation and Mitochondrial Biogenesis

(2009) B. Haas et al.   Science Signaling

Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor- and Drug-Induced Apoptosis

(2008) D. Opel et al.   CANCER RESEARCH

Deregulation of the Akt Pathway in Human Cancer

(2008) Eriko Tokunaga et al.   CURRENT CANCER DRUG TARGETS

Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide

(2008) Tobias Sinnberg et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Brain Cancer Stem Cells Display Preferential Sensitivity to Akt Inhibition

(2008) Christine E. Eyler et al.   STEM CELLS